Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back.

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...

The company reported $10 million in mRESVIA (RSV vaccine) sales in the third quarter of 2024. Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...